Clinical Trial News and Research

RSS

Medica Research Institute launched for applying innovation to healthcare delivery

Medica today announced the launch of the Medica Research Institute as a non-profit company that will serve as the research arm within the broader organization. Built on the principals of systematic investigation, some potential areas of study include health services research, comparative effectiveness research and clinical trial studies.

9 Mar 2010

invendo medical seeks premarket clearance for new C20 colonoscopy system

invendo medical announced today that the company has filed its 510(k) notice submission with the Food and Drug Administration for premarket clearance of the company's new C20™ colonoscopy system including the SC20™ single-use colonoscope. This is the first FDA submission for invendo medical in the United States.

8 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.

8 Mar 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.

8 Mar 2010

KCI receives reimbursement approval for use of V.A.C. ATS Therapy System in Japan

Kinetic Concepts, Inc. today announced it has received reimbursement approval from Japan’s Health Insurance Bureau for use of the innovative V.A.C. ATS® Therapy System in the country. The approval signifies an important advancement in the company’s plans for market launch in April and follows Japan’s Ministry of Health, Labor and Welfare’s decision in November 2009 to grant final regulatory approval for the product.

8 Mar 2010

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Health Affairs this month is devoted to the topic of childhood obesity, with the first study of the group - National, State, And Local Disparities In Childhood Obesity - pointing out that "new data from the 2007 National Survey of Children's Health show that the percentage of children ages 10-17 who are overweight ... remained stable, while the national prevalence of obesity (BMI in the ninety-fifth percentile and higher) grew significantly, from 14.8 percent in 2003 to 16.4 percent in 2007.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

New anti-tumour vaccine for mesothelioma shows promising results

A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.

5 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

Insurance and risk management challenges in overseas clinical trials for U.S.-based life sciences companies

The ACE Group of insurance and reinsurance companies today announced the availability of an informational white paper focusing on insurance and risk management issues faced by life sciences companies as they conduct business in the U.S. and globally. The paper, “Managing the Complex Challenges of a Global Insurance Program: Foreign Clinical Trials Case Study,” appeared in the November issue of John Liner Review, and is part of ACE Progress ReportsSM, a collection of white papers, articles and executive reports on current and emerging risk management issues.

5 Mar 2010

Successful periodontal treatment reduces preterm birth risk

Previous studies have explored the effect of periodontal treatment, irrespective of efficacy of treatment, in reducing infant prematurity. In a study titled "Risk of Preterm Birth Is Reduced with Successful Periodontal Treatment," lead researcher M. Jeffcott, and colleagues S. Parry and M. Sammel (all from the University of Pennsylvania, Philadelphia) and G. Macones (Washington University, St. Louis, Missouri) determined whether a reduction in infant prematurity was associated with successful periodontal treatment.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

BioClinica announces partnerships with Health Sciences International and PRL Central Laboratory Services

BioClinica™, Inc.,, a global provider of clinical trial management services, today announced it has created strategic partnerships with two clinical research organizations (CROs), Health Sciences International, Inc., and PRL Central Laboratory Services. Both alliances strengthen the BioClinica Certified Partner Program, a group of VIP CRO partners chosen based on therapeutic expertise and customer satisfaction.

From Clario 5 Mar 2010

Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

4 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Clinical Trial News and Research

Medica Research Institute launched for applying innovation to healthcare delivery

invendo medical seeks premarket clearance for new C20 colonoscopy system

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Rexahn Pharmaceuticals granted Japanese patent for Archexin

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

KCI receives reimbursement approval for use of V.A.C. ATS Therapy System in Japan

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

New anti-tumour vaccine for mesothelioma shows promising results

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Insurance and risk management challenges in overseas clinical trials for U.S.-based life sciences companies

Successful periodontal treatment reduces preterm birth risk

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

BioClinica announces partnerships with Health Sciences International and PRL Central Laboratory Services

Enigma Diagnostics opens new Regional HQ office in San Diego

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News